Research Retracted papers originating from paper mills: cross sectional study Cristina Candal-Pedreira, Joseph S Ross, Alberto Ruano-Ravina, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-071517 (Published 28 November 2022)Cite this as: BMJ 2022;379:e071517 Abstract Objectives To describe retracted papers originating from paper mills, including their characteristics, visibility, and impact over time, and the journals in which they were publi...

ARTICLES|ONLINE FIRST Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial Toby M Maher, Veronica A Tudor, Peter Saunders, et al. Lancet Respir Med Published:November 11, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00359-9 Summary Background Rituximab is often used as rescue therapy in in...

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial  Marisa Holubar,  Aruna Subramanian,  Natasha Purington,  et al Clinical Infectious Diseases, Volume 75, Issue 11, 1 December 2022, Pages 1883–1892, https://doi.org/10.1093/cid/ciac312 Abstract Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitroactivity...

Research Changing patterns in reporting and sharing of review data in systematic reviews with meta-analysis of the effects of interventions: cross sectional meta-research study Phi-Yen Nguyen, Raju Kanukula, Joanne E McKenzie, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-072428 (Published 22 November 2022)Cite this as: BMJ 2022;379:e072428 Abstract Objectives To examine changes in completeness of reporting and frequency of sharing data, an...

ORIGINAL ARTICLE Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network N Engl J Med January 21, 2023DOI: 10.1056/NEJMoa2212663 Abstract BACKGROUND Intravenous fluids and vasopressor agents are commonly used in early resuscitation of patients with sepsis, but comparative data for prioritizing their delivery are l...

Research Impact of community asymptomatic rapid antigen testing on covid-19 related hospital admissions: synthetic control study Xingna Zhang, Ben Barr, Mark Green, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-071374 (Published 23 November 2022)Cite this as: BMJ 2022;379:e071374 Abstract Objective To analyse the impact of voluntary rapid testing for SARS-CoV-2 antigen in Liverpool city on covid-19 related hospital admissions. Design&nbs...

ARTICLES| VOLUME 10, ISSUE 12, P1137-1146, DECEMBER 01, 2022 Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Alexander P J Vlaar, Martin Witzenrath, Pieter van Paassen, et al. Lancet Respir Med 2022; 10: 1137-1146 Published:September 07, 2022 DOI: https://doi.org/10.1016/S2213-2600(22)00297-1 ...

Research Letter  Climate Change and Health December 20, 2022 Association Between the 2021 Heat Wave in Portland, Oregon, and Seattle, Washington, and Emergency Department Visits Amruta Nori-Sarma, Chad Milando, Kate R. Weinberger, et al JAMA. 2022;328(23):2360-2362. doi:10.1001/jama.2022.20665 Heat waves are becoming more frequent and severe, with pronounced effects on human health.1 In late June 2021, temperatures in the US Pacific N...

Original Investigation  Caring for the Critically Ill Patient December 16, 2022 Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial Writing Committee for the REMAP-CAP Investigators JAMA. Published online December 16, 2022. doi:10.1001/jama.2022.23257 Key Points Question  What is the effect of treatment for critically ill patients with COVID-19 on longer-term mortali...

Research Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial Walter Ageno, Lorenza Bertù, Eugenio Bucherini, et al BMJ 2022; 379 doi: https://doi.org/10.1136/bmj-2022-072623 (Published 23 November 2022)Cite this as: BMJ 2022;379:e072623 Abstract Objective To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated di...